priors.science/reviews/psoriasis-psoriatic-arthritis

Psoriasis Psoriatic Arthritis

The current evidence on 27 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

27claims tracked
234primary papers reviewed
27 Sep 2026latest evidence review
11 Established · 9 Likely · 3 Uncertain · 0 Doubtful · 4 Refuted  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
IL-17 inhibitors versus ustekinumab PASI 90Pso Il17Established90%8
Risankizumab versus ustekinumab PASI 90Pso Il23Established90%10
Guselkumab 2-year PASI 90 durabilityPso Il23Established90%8
Tofacitinib ACR20 in psoriatic arthritisPsa JAKEstablished90%8
Risankizumab minimal disease activity in psoriatic arthritisPsa PJTEstablished90%23
Bimekizumab ACR50 in biologic-naive psoriatic arthritisPsa PJTEstablished90%8
Secukinumab ASAS20 in axial psoriatic arthritisPsa AxlEstablished88%7
Guselkumab ACR20 in biologic-naive psoriatic arthritisPsa PJTEstablished87%8
Deucravacitinib versus apremilast PASI 75Pso SMEstablished87%9
Apremilast PASI 75 efficacyPso SMEstablished87%9
Secukinumab 5-year ACR20 durabilityPsa PJTEstablished86%9
Bimekizumab versus secukinumab PASI 90Pso Il17Likely84%8
Tofacitinib major adverse cardiovascular events versus TNF inhibitors in rheumatoid arthritisPsa JsafLikely83%9
Upadacitinib ACR50 versus placebo in TNF-inhibitor inadequate respondersPsa JAKLikely80%6
IL-17 inhibitors associated with inflammatory bowel disease incidencePsa CVDLikely74%8
Upadacitinib versus adalimumab in biologic-naive psoriatic arthritisPsa JAKLikely74%8
Secukinumab pooled PASI 90 responsePso Il17Likely73%10
Psoriasis as independent cardiovascular risk factorPsa CVDLong-standingLikely72%10
Biologics reduce psoriasis cardiovascular disease riskPsa CVDLikely72%8
JAK inhibitors venous thromboembolism riskPsa JsafLikely72%12
HLA-Cw6 predicts ustekinumab responsePsa BMKLong-standingUncertain62%8
Treat-to-target improves psoriatic arthritis outcomesPsa BMKLong-standingUncertain60%8
Ixekizumab PASI 100 response ratesPso Il17Long-standingUncertain56%9
IL-23p19 inhibitors post-withdrawal durabilityPso Il23Refuted22%8thin basis
IL-17 inhibitors: axial psoriatic arthritis versus axial spondyloarthritis responsePsa AxlRefuted20%8
Ixekizumab versus adalimumab ACR50 in psoriatic arthritisPsa PJTRefuted15%8
JAK cardiovascular risk signal extends to psoriatic arthritisPsa JsafRefuted10%10
Track Psoriasis Psoriatic Arthritis.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.